← Back to Search

Other

Active Treatment (HB-01) for Panic Disorder

Phase 2

Waitlist Available

Led By David Walling

Research Sponsored by Honeybrains Biotech LLC

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, week 2, week 4, week 8 and week 12

Awards & highlights

Study Summary

This trial will test if a new drug, HB-1, is safe and effective for treating Panic Disorder in adults.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, week 2, week 4, week 8 and week 12

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, week 2, week 4, week 8 and week 12

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, week 2, week 4, week 8 and week 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in Clinical Global Impression-Severity Scale (CGI-I)

Change in Panic Disorder Symptom Severity Scale (PDSS)

Incidence of Treatment-Emergent Adverse Events

+1 more

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Active Treatment (HB-01)Active Control1 Intervention

Approximately 40 patients will receive HB-01 active study drug.

Group II: Placebo TreatmentPlacebo Group1 Intervention

Approximately 40 patients will receive a matched placebo.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Honeybrains Biotech LLCLead Sponsor

Cognitive Research CorporationIndustry Sponsor

23 Previous Clinical Trials

2,244 Total Patients Enrolled

David WallingPrincipal InvestigatorCollaborative NeuroScience Research, Garden Grove, CA

1 Previous Clinical Trials

69 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current geographic scope of this research endeavor?

"A number of medical institutions are currently taking part in the trial, such as CNS Healthcare in Memphis, Lumos Psychiatric Services in San Jose and Richmond Behavioral Associates in Orlando. Additionally, there are 10 other sites involved worldwide."

Answered by AI

Who qualifies to participate in this research endeavor?

"Eligible candidates for this research trial must suffer from panic attacks, and be within the age range of 18 to 60. At present, a total of 86 individuals have been recruited."

Answered by AI

Is this experiment offering enrollment to seniors over the age of seventy-five?

"This medical trial accepts applicants between the ages 18 and 60. Additionally, there are 3 studies for individuals younger than eighteen while 24 trials are available to those above sixty-five years old."

Answered by AI

Is enrollment still open for participation in this experiment?

"Clinicaltrials.gov reveals that this clinical trial, which was originally posted on February 3rd 2022 and last updated on September 22nd 2022, is not currently recruiting participants. Nevertheless, there are 34 other trials in progress that require medical volunteers."

Answered by AI

Has the FDA sanctioned HB-01 for therapeutic purposes?

"Power's assessment of the safety of Active Treatment (HB-01) is a 2, as it has only gone through Phase 2 trials and therefore lacks data demonstrating its efficacy."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Safety and Efficacy of HB-1 for Panic Disorder

2022. "Safety and Efficacy of HB-1 for Panic Disorder". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05071430.